Barry A. Borlaug MD
Associate Professor of Medicine; Director, Circulatory Failure Research, Mayo Clinic, Rochester, MinnesotaDr. Borlaug is a board certified cardiologist, specializing in heart failure and invasive hemodynamic assessment, where he cares for heart failure patients on a regular basis in both the clinics and hospital. He has conducted and collaborated on a number of studies examining the mechanisms of exercise tolerance using both invasive and noninvasive methods in patients with heart failure and is keenly interested in the pathophysiologic underpinnings for exercise tolerance and fatigue in heart failure.
Recent Contributions to PracticeUpdate:
- Effectiveness of Tirzepatide in Patients With HFpEF and Obesity
- Validation of the HFpEF-ABA Score for HFpEF Screening
- Rate-Adaptive Atrial Pacing in Patients With HFpEF and Chronotropic Incompetence
- Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic HFrEF
- Prevalence and Prognostic Significance of Microvascular Dysfunction in HFpEF
- β-Blocker Withdrawal May Improve Functional Capacity in Heart Failure and Preserved Ejection Fraction
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With HFpEF
- Exercise-Stress Real-Time CMR Imaging for Noninvasive Characterization of HFpEF
- Application of Diagnostic Algorithms for HFpEF to the Community
- Gender-Related Differences in HFpEF